Zura Bio to Participate in Guggenheim Biotech Summit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy ZURA?
Source: Newsfilter
- Executive Participation: Zura Bio's senior leadership team will participate in a fireside chat at the Guggenheim Biotech Summit on February 11, 2026, in New York, which is expected to attract investor attention and enhance the company's visibility.
- One-on-One Investor Meetings: On the same day, Zura will conduct one-on-one investor meetings, providing potential investors with an opportunity to gain deeper insights into the company's pipeline and strategy, potentially facilitating capital inflow.
- Clinical Stage Pipeline: Zura is developing dual-pathway antibodies for autoimmune and inflammatory diseases, with its lead candidate tibulizumab undergoing two Phase 2 clinical studies aimed at improving efficacy and safety to meet unmet market needs.
- Candidate Drug Progress: In addition to tibulizumab, Zura's other candidates crebankitug and torudokimab have completed Phase 1 studies and are being evaluated for their potential across various autoimmune and inflammatory conditions, showcasing the company's innovative capabilities in biopharmaceuticals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZURA
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 16.50 USD with a low forecast of 15.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.670
Low
15.00
Averages
16.50
High
18.00
Current: 5.670
Low
15.00
Averages
16.50
High
18.00
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zura Bio to Participate in Guggenheim Biotech Summit Fireside Chat
- Executive Participation: Zura Bio's senior leadership team will participate in a fireside chat at the Guggenheim Biotech Summit on February 11, 2026, in New York, showcasing the company's innovative drug development in autoimmune and inflammatory diseases.
- Investor Meeting Schedule: On the same day, the company will conduct one-on-one investor meetings aimed at strengthening communication with potential investors, thereby enhancing market awareness and investment confidence in Zura Bio.
- Clinical Trial Progress: Zura's lead product candidate, tibulizumab (ZB-106), is currently undergoing two Phase 2 clinical studies in adults targeting hidradenitis suppurativa and systemic sclerosis, indicating the company's potential in addressing unmet medical needs.
- Multi-Asset Pipeline: In addition to tibulizumab, Zura is evaluating other candidates, including crebankitug (ZB-168) and torudokimab (ZB-880), which have completed Phase 1/1b studies, further expanding treatment options in autoimmune and inflammatory diseases.
See More
Zura Bio to Participate in Guggenheim Biotech Summit
- Executive Participation: Zura Bio's senior leadership team will participate in a fireside chat at the Guggenheim Biotech Summit on February 11, 2026, in New York, which is expected to attract investor attention and enhance the company's visibility.
- One-on-One Investor Meetings: On the same day, Zura will conduct one-on-one investor meetings, providing potential investors with an opportunity to gain deeper insights into the company's pipeline and strategy, potentially facilitating capital inflow.
- Clinical Stage Pipeline: Zura is developing dual-pathway antibodies for autoimmune and inflammatory diseases, with its lead candidate tibulizumab undergoing two Phase 2 clinical studies aimed at improving efficacy and safety to meet unmet market needs.
- Candidate Drug Progress: In addition to tibulizumab, Zura's other candidates crebankitug and torudokimab have completed Phase 1 studies and are being evaluated for their potential across various autoimmune and inflammatory conditions, showcasing the company's innovative capabilities in biopharmaceuticals.
See More
Progress Software Corp Reports Q4 EPS Beat, Shares Surge 20.5%
- Earnings Beat: Progress Software reported an adjusted Q4 EPS of $1.51, exceeding the market expectation of $1.31, indicating strong profitability growth that is likely to boost investor confidence.
- Revenue Performance: The company's quarterly revenue was $252.67 million, slightly below the consensus estimate of $252.86 million; however, the overall financial performance remains robust, potentially attracting more institutional investor interest.
- Significant Stock Surge: Following the positive earnings report, Progress Software's shares surged 20.5% to $46.50 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: The company issued first-quarter and FY26 guidance above market estimates, demonstrating management's confidence in future performance, which may further drive stock price increases and enhance market recognition of its long-term investment value.
See More
Zura Bio Appoints Sandeep Kulkarni as CEO Effective January 21, 2026
- Executive Appointment: Zura Bio has announced the appointment of Sandeep Kulkarni as CEO, effective January 21, 2026, with Kulkarni also continuing as a director, marking a significant leadership change for the company.
- Interim CEO Transition: Kulkarni succeeds Kim Davis, who has served as interim CEO since October 2025 during Robert Lisicki's medical leave, ensuring continuity in management during a critical period.
- Board Member Experience: Kulkarni has been a member of Zura's Board of Directors since the company's business combination and Nasdaq listing in March 2023, bringing valuable industry experience that will provide strategic guidance for future growth.
- CEO Resignation: Current CEO Robert Lisicki will resign effective January 21, 2026, ending his leadership role, which may impact investor confidence regarding the company's future direction.
See More
Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
Zura Bio to Participate in Guggenheim Biotech Summit Fireside Chat
- Executive Participation: Zura Bio's senior leadership team will participate in a fireside chat at the Guggenheim Biotech Summit on February 11, 2026, in New York, showcasing the company's innovative drug development in autoimmune and inflammatory diseases.
- Investor Meeting Schedule: On the same day, the company will conduct one-on-one investor meetings aimed at strengthening communication with potential investors, thereby enhancing market awareness and investment confidence in Zura Bio.
- Clinical Trial Progress: Zura's lead product candidate, tibulizumab (ZB-106), is currently undergoing two Phase 2 clinical studies in adults targeting hidradenitis suppurativa and systemic sclerosis, indicating the company's potential in addressing unmet medical needs.
- Multi-Asset Pipeline: In addition to tibulizumab, Zura is evaluating other candidates, including crebankitug (ZB-168) and torudokimab (ZB-880), which have completed Phase 1/1b studies, further expanding treatment options in autoimmune and inflammatory diseases.
See More
Zura Bio to Participate in Guggenheim Biotech Summit
- Executive Participation: Zura Bio's senior leadership team will participate in a fireside chat at the Guggenheim Biotech Summit on February 11, 2026, in New York, which is expected to attract investor attention and enhance the company's visibility.
- One-on-One Investor Meetings: On the same day, Zura will conduct one-on-one investor meetings, providing potential investors with an opportunity to gain deeper insights into the company's pipeline and strategy, potentially facilitating capital inflow.
- Clinical Stage Pipeline: Zura is developing dual-pathway antibodies for autoimmune and inflammatory diseases, with its lead candidate tibulizumab undergoing two Phase 2 clinical studies aimed at improving efficacy and safety to meet unmet market needs.
- Candidate Drug Progress: In addition to tibulizumab, Zura's other candidates crebankitug and torudokimab have completed Phase 1 studies and are being evaluated for their potential across various autoimmune and inflammatory conditions, showcasing the company's innovative capabilities in biopharmaceuticals.
See More
Progress Software Corp Reports Q4 EPS Beat, Shares Surge 20.5%
- Earnings Beat: Progress Software reported an adjusted Q4 EPS of $1.51, exceeding the market expectation of $1.31, indicating strong profitability growth that is likely to boost investor confidence.
- Revenue Performance: The company's quarterly revenue was $252.67 million, slightly below the consensus estimate of $252.86 million; however, the overall financial performance remains robust, potentially attracting more institutional investor interest.
- Significant Stock Surge: Following the positive earnings report, Progress Software's shares surged 20.5% to $46.50 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Optimistic Guidance: The company issued first-quarter and FY26 guidance above market estimates, demonstrating management's confidence in future performance, which may further drive stock price increases and enhance market recognition of its long-term investment value.
See More
Zura Bio Appoints Sandeep Kulkarni as CEO Effective January 21, 2026
- Executive Appointment: Zura Bio has announced the appointment of Sandeep Kulkarni as CEO, effective January 21, 2026, with Kulkarni also continuing as a director, marking a significant leadership change for the company.
- Interim CEO Transition: Kulkarni succeeds Kim Davis, who has served as interim CEO since October 2025 during Robert Lisicki's medical leave, ensuring continuity in management during a critical period.
- Board Member Experience: Kulkarni has been a member of Zura's Board of Directors since the company's business combination and Nasdaq listing in March 2023, bringing valuable industry experience that will provide strategic guidance for future growth.
- CEO Resignation: Current CEO Robert Lisicki will resign effective January 21, 2026, ending his leadership role, which may impact investor confidence regarding the company's future direction.
See More
Worthington Steel (WS) Enters Acquisition Agreement with Kloeckner & Co, Shares Surge 6.9%
- Acquisition Agreement: Worthington Steel Inc has entered into a Business Combination Agreement with Kloeckner & Co, planning a voluntary public offer to acquire all outstanding shares at €11 per share ($12.8), with management support and existing leadership expected to remain post-closing, thereby enhancing the company's market position and future growth potential.
- Stock Surge: Following the acquisition announcement, Worthington Steel's shares jumped 6.9% to $41.43, reflecting positive market expectations and increased investor confidence, which may provide financial support for the company's future developments.
- Industry Dynamics: On the same trading day, Kopin Corp shares rose 17.1% to $3.46, and ImmunityBio Inc shares increased by 17% to $4.62, indicating strong demand in the biotech and manufacturing sectors, potentially creating more investment opportunities for related companies.
- Positive Market Reaction: The overall market showed mixed performance, with the Nasdaq Composite gaining around 100 points, demonstrating continued investor interest and confidence in tech stocks, which may create a favorable market environment for Worthington Steel's acquisition plans.
See More
Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab
- Stock Plunge: Ultragenyx Pharmaceutical's shares fell sharply by 42% to $19.84 on Monday, primarily due to the failure of its Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta, leading to a significant decline in market confidence.
- Clinical Trial Failure: The results from Mereo BioPharma and Ultragenyx indicated that setrusumab did not achieve statistical significance in reducing the annualized clinical fracture rate, which not only impacts the company's short-term financial performance but may also have long-term negative implications for its future R&D investments and market competitiveness.
- Severe Market Reaction: The disappointing trial results raised investor concerns about Ultragenyx's future prospects, resulting in a substantial decrease in its market capitalization, reflecting the high sensitivity of investors to the success or failure of clinical trials in the biopharmaceutical sector.
- Industry Impact: Ultragenyx's failure could have a ripple effect across the biopharmaceutical industry, particularly in the bone metabolism disease space, as investors may adopt a more cautious approach towards similar product developments, potentially affecting financing and R&D strategies of related companies.
See More
